Rilmenidine Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Rilmenidine
Therapeutic Class: Antihypertensive
Subclass: Centrally acting imidazoline receptor agonist
Speciality: Cardiology
Subclass: Centrally acting imidazoline receptor agonist
Speciality: Cardiology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
• Tablets: 1 mg
Route(s): Oral
Formulations Available in India:
• Tablets: 1 mg
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ Essential Hypertension (mild to moderate)
| Parameter | Recommendation |
|
Starting dose
|
1 mg once daily, preferably in the morning |
|
Titration
|
If response inadequate after 2–3 weeks, increase to 1 mg twice daily |
|
Usual maintenance dose
|
1–2 mg daily, in 1 or 2 divided doses |
|
Maximum dose
|
2 mg/day |
Clinical Notes:
• May be used as monotherapy or in combination with other antihypertensives such as diuretics, calcium channel blockers, or ACE inhibitors
• Has favourable metabolic profile — minimal impact on glucose and lipid parameters
• Better tolerated than clonidine with less sedation due to selective imidazoline receptor activity
• Avoid abrupt discontinuation — taper gradually to prevent rebound hypertension
• May be used as monotherapy or in combination with other antihypertensives such as diuretics, calcium channel blockers, or ACE inhibitors
• Has favourable metabolic profile — minimal impact on glucose and lipid parameters
• Better tolerated than clonidine with less sedation due to selective imidazoline receptor activity
• Avoid abrupt discontinuation — taper gradually to prevent rebound hypertension
Secondary Indications — Adults (Off-label, if any)
▶ Resistant Hypertension (as add-on therapy) — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
1 mg once daily |
|
Titration
|
May increase to 1 mg twice daily based on response |
|
Usual maintenance dose
|
1–2 mg daily in divided doses |
|
Maximum dose
|
2 mg/day |
|
Duration
|
Long-term as per blood pressure control |
• Specialist only
• Evidence basis: Limited evidence from small European studies; occasionally used in Indian specialist hypertension practice where first- and second-line agents are inadequate or not tolerated
• Evidence basis: Limited evidence from small European studies; occasionally used in Indian specialist hypertension practice where first- and second-line agents are inadequate or not tolerated
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable — Rilmenidine is not recommended in children and adolescents due to lack of safety and efficacy data.
Clear statement: Use not established below 18 years of age — avoid unless in controlled clinical trial setting or under specialist hypertension unit guidance.
Secondary Indications — Paediatric Doses (Off-label, if any)
Not applicable — No established paediatric off-label indications in Indian or international practice.
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| eGFR ≥30 mL/min/1.73m² | No dose adjustment required |
| eGFR 15–29 mL/min/1.73m² | Start with 1 mg once daily; use with caution; monitor blood pressure and for signs of bradycardia |
| eGFR <15 mL/min/1.73m² | Avoid unless under specialist supervision |
| Haemodialysis | Limited data; use with caution under specialist guidance |
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | No dose adjustment required |
| Moderate impairment | Use with caution; initiate at 1 mg once daily; monitor for CNS adverse effects |
| Severe impairment | Avoid use — increased CNS exposure expected; no safety data available |
CONTRAINDICATIONS
• Known hypersensitivity to rilmenidine or imidazoline derivatives
• Severe depression
• Severe hepatic failure
• Severe renal impairment (eGFR <15 mL/min/1.73m²) without specialist oversight
• Sick sinus syndrome or severe bradycardia (unless pacemaker in situ)
• Severe depression
• Severe hepatic failure
• Severe renal impairment (eGFR <15 mL/min/1.73m²) without specialist oversight
• Sick sinus syndrome or severe bradycardia (unless pacemaker in situ)
CAUTIONS
• History of depressive disorders — risk of exacerbation
• Coronary artery disease — risk of rebound hypertension if abruptly discontinued
• Bradyarrhythmias — may worsen due to central sympatholytic effect
• Recent cerebrovascular accident
• Heart failure
• Peripheral vascular disease
• Concurrent use of CNS depressants
• Abrupt withdrawal must be avoided — taper slowly to prevent rebound hypertension
• Coronary artery disease — risk of rebound hypertension if abruptly discontinued
• Bradyarrhythmias — may worsen due to central sympatholytic effect
• Recent cerebrovascular accident
• Heart failure
• Peripheral vascular disease
• Concurrent use of CNS depressants
• Abrupt withdrawal must be avoided — taper slowly to prevent rebound hypertension
PREGNANCY
| Consideration | Recommendation |
| Overall safety | Insufficient human data; use with caution |
| Risk | Potential for fetal effects based on mechanism; limited safety information |
| When it may be used | Only if benefit clearly outweighs risk and preferred alternatives are poorly tolerated |
| Preferred alternatives | Methyldopa or labetalol are better established in Indian obstetric practice |
| Monitoring | Maternal blood pressure, fetal growth, and wellbeing if used |
LACTATION
| Consideration | Recommendation |
| Compatibility | Limited data; compatibility uncertain |
| Drug levels in milk | Likely low levels based on pharmacokinetic properties |
| Preferred alternatives | Labetalol or nifedipine during breastfeeding |
| Infant monitoring | Sedation, hypotonia, feeding difficulty, poor weight gain |
ELDERLY
| Consideration | Recommendation |
| Starting dose | 1 mg once daily |
| Titration | Slower titration recommended — increased sensitivity to CNS effects |
| Risks | Drowsiness, dizziness, orthostatic hypotension, falls |
| Monitoring | Blood pressure (including orthostatic), renal function periodically, mental status assessment |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Mechanism | Recommendation |
| Beta-blockers | Additive bradycardia and hypotension; risk of severe rebound hypertension if either drug abruptly withdrawn |
Avoid abrupt withdrawal of either agent; taper gradually
|
| Tricyclic antidepressants | May antagonise antihypertensive effect via alpha-adrenergic blockade |
Avoid concurrent use
|
| MAO inhibitors | Theoretical risk of hypertensive reaction |
Avoid combination
|
| CNS depressants (benzodiazepines, alcohol, opioids) | Enhanced sedative effects |
Avoid or use with extreme caution
|
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Mechanism | Recommendation |
| Diuretics | Additive antihypertensive effect | Monitor blood pressure, especially in volume-depleted patients |
| ACE inhibitors/ARBs | Additive antihypertensive effect | Generally safe; monitor for hypotension when initiating combination |
| Calcium channel blockers | Additive blood pressure lowering | Monitor blood pressure; may require dose adjustment |
| Digoxin | Additive bradycardia risk | Monitor heart rate |
COMMON ADVERSE EFFECTS
• Dry mouth
• Drowsiness
• Fatigue
• Dizziness
• Headache
• Asthenia
• Gastrointestinal discomfort (mild nausea, abdominal pain)
• Insomnia (less common)
• Drowsiness
• Fatigue
• Dizziness
• Headache
• Asthenia
• Gastrointestinal discomfort (mild nausea, abdominal pain)
• Insomnia (less common)
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Note |
| Severe bradycardia | Rare; discontinue if symptomatic |
| Depression or worsening of psychiatric symptoms | Monitor mental status; discontinue if significant |
| Rebound hypertension | If abruptly discontinued; may require hospitalisation if severe |
| Hypersensitivity reactions | Rare; discontinue immediately |
| Syncope | Due to excessive hypotension; more common in elderly |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Blood pressure, heart rate, renal function, mental health history |
|
After initiation/dose change
|
Blood pressure after 1–2 weeks; assess for sedation or depression symptoms |
|
Long-term
|
Quarterly blood pressure monitoring; periodic renal function assessment; mental status evaluation especially in elderly |
BRANDS AVAILABLE IN INDIA
• Hyperium (Serdia Pharmaceuticals)
• Rilways (Intas Pharmaceuticals)
• Rilways (Intas Pharmaceuticals)
Note: Limited availability compared to other antihypertensives; may require special order in some regions
PRICE RANGE (INR)
• ₹4–₹10 per tablet (1 mg) in private retail pharmacies
• Not included in NLEM
• Generic versions may be available
• May be available in select government NCD clinics in some states
• Not included in NLEM
• Generic versions may be available
• May be available in select government NCD clinics in some states
CLINICAL PEARLS
• Consider rilmenidine when clonidine causes excessive sedation — rilmenidine has better CNS tolerability due to selective imidazoline receptor (I1) activity over alpha-2 adrenoceptors
• Useful in hypertensive patients with metabolic syndrome due to neutral effects on glucose and lipid profile
• Abrupt discontinuation can cause dangerous rebound hypertension — always taper gradually over 1–2 weeks
• Avoid concurrent use with tricyclic antidepressants as they may blunt antihypertensive effect
• Monitor closely in elderly patients and those with psychiatric history for CNS adverse effects
• Not a first-line agent — reserve for patients intolerant to or inadequately controlled on standard antihypertensives
• Useful in hypertensive patients with metabolic syndrome due to neutral effects on glucose and lipid profile
• Abrupt discontinuation can cause dangerous rebound hypertension — always taper gradually over 1–2 weeks
• Avoid concurrent use with tricyclic antidepressants as they may blunt antihypertensive effect
• Monitor closely in elderly patients and those with psychiatric history for CNS adverse effects
• Not a first-line agent — reserve for patients intolerant to or inadequately controlled on standard antihypertensives
TAGS
rilmenidine; hypertension; antihypertensive; centrally acting; imidazoline agonist; metabolic-neutral; renal-caution; pregnancy-caution; elderly-caution; Schedule H
VERSION
RxIndia v1.0 — 19 Feb 2026
REFERENCES
• CDSCO
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• API Textbook of Medicine
• AIIMS Antihypertensive Protocols
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• European clinical data (referenced for off-label use — clearly marked)
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• API Textbook of Medicine
• AIIMS Antihypertensive Protocols
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• European clinical data (referenced for off-label use — clearly marked)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.